Tags : Myriad

Weekly Snapshot

PharmaShots Weekly Snapshots (May 03 – 07, 2021)

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer Published: May 7, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab, Tremelimumab, P-III, POSEIDON Study, Stage IV Non-Small Cell Lung Cancer Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + […]Read More

MedTech

Labcorp to Acquire Myriad’s Vectra Testing Business for $150M

Shots: Labcorp acquires the Vectra RA test from Myriad Genetics along with other operating assets and IP for $150M in cash. The transaction is expected to close in Q3’21 The divestiture of Myriad auto immune’s Vectra testing business allow Labcorb to bolster its rheumatology and autoimmune portfolios Vectra is a non-invasive, blood-based test that analyzes […]Read More

MedTech

Myriad to File sPMA to the US FDA of BRACAnalysis

Shots: Myriad to seek approval based on the P-III PROfound results assessing Lynparza vs enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have failed prior treatment with the hormonal agent with homologous recombination repair gene mutations In 2007, Myriad & AstraZeneca entered into collaboration on Lynparza and has resulted in multiple […]Read More

Pharma

Myriad and Pfizer Signs a Service Agreement for Testing of

Shots: Myriad to provide BRACAnalysis CDx testing device in P-II study conducted to evaluate Pfizer’s talazoparib for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer BRACAnalysis CDx is an IVD device used for qualitative detection and classification of protein coding regions & intron/exon boundaries of BRCA1 and BRCA2 gene In April, 2015 Myriad and […]Read More